Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given a consensus rating of “Buy” by the twenty ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $111.50.
Several analysts have recently commented on ALNY shares. UBS Group increased their price target on shares of Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, September 4th. BidaskClub lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $93.00 price target on the stock. in a research report on Wednesday, September 18th. Nomura set a $62.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “sell” rating in a research report on Tuesday, October 8th. Finally, Barclays restated a “buy” rating and set a $125.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 7th.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 49,456 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, October 14th. The shares were sold at an average price of $79.45, for a total value of $3,929,279.20. Following the transaction, the chief executive officer now owns 239,449 shares in the company, valued at approximately $19,024,223.05. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Barry E. Greene sold 58,913 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $89.99, for a total transaction of $5,301,580.87. Following the completion of the transaction, the president now owns 111,851 shares in the company, valued at approximately $10,065,471.49. The disclosure for this sale can be found here. 3.60% of the stock is owned by company insiders.
NASDAQ ALNY traded up $1.59 during trading hours on Monday, hitting $92.05. The company had a trading volume of 362,900 shares, compared to its average volume of 602,539. The business has a 50 day moving average of $84.86 and a 200-day moving average of $78.13. The company has a market cap of $10.10 billion, a PE ratio of -12.16 and a beta of 2.37. Alnylam Pharmaceuticals has a 1-year low of $60.27 and a 1-year high of $96.08. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.22 and a current ratio of 5.38.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) EPS for the quarter, beating the consensus estimate of ($2.17) by $0.25. The business had revenue of $70.06 million for the quarter, compared to analyst estimates of $57.14 million. Alnylam Pharmaceuticals had a negative net margin of 485.73% and a negative return on equity of 52.88%. The company’s quarterly revenue was up 3284.5% on a year-over-year basis. During the same period in the prior year, the business earned ($1.56) earnings per share. Sell-side analysts expect that Alnylam Pharmaceuticals will post -7.9 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Article: What is meant by a buy rating?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.